


Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 2

**Complete If Known**

Application Number	09/815,340
Filing Date	March 23, 2001
First Named Inventor	Bert VOGELSTEIN
Group Art Unit	1645
Examiner Name	

**RECEIVED**

NOV 13 2001

TECH CENTER 1600/2900

Attorney Docket Number 001107.00074

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KAC		Andrew BUSH et al, "c-myc null cells misregulate cad and gadd45 but not other proposed c-Myc targets", Genes & Development, Vol. 12, 1998, pp. 3797-3802.	
		Hitoshi MATSUSHIME et al, "Identification and Properties of an Atypical Catalytic Subunit (p34 <sup>PSK-J3</sup> /cdk4) for Mammalian D Type G1 Cyclins", Cell, Vol. 71, 1992, pp. 323-334.	
		Martins EILERS et al, "The MYC protein activates transcription of the $\alpha$ -prothymosin gene", The EMBO Journal, Vol. 10, No. 1, 1991, pp. 133-141.	
		Mark E. EWEN et al, "TGF $\beta$ Inhibition of Cdk4 Synthesis Is Linked to Cell Cycle Arrest", Cell, Vol. 74, 1993, pp. 1009-1020.	
		Heiko HERMEKING et al, "Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21", Oncogene, Vol. 11, 1995, pp. 1409-1415.	
		Kathryn M. LATHAM et al, "Inhibition of p53-Mediated Growth Arrest by Overexpression of Cyclin-Dependent Kinases", Molecular and Cellular Biology, Vol. 16, No. 8, 1996, pp. 4445-4455.	
		Jim WANG et al, "Myc activates telomerase", Genes & Development, Vol. 12, 1998, pp. 1769-1774.	
		Abdel G. ELKAHLOUN et al, "Transcript Mapping in a 46-kb Sequenced Region at the Core of 12q13.3 Amplification in Human Cancers", Genomics, Vol. 42, 1997, pp. 295-301.	
		Maria K. MATEYAK et al, "Phenotypes of c-Myc-deficient Rat Fibroblasts Isolated by Targeted Homologous Recombination", Cell Growth & Differentiation, Vol. 8, 1997, pp. 1039-1048.	
		Philipp STEINER et al, "Identification of a Myc-dependent step during the formation of active G <sub>1</sub> cyclin-cdk complexes", The EMBO Journal, Vol. 14, No. 19, 1995, pp. 4814-4826.	
✓		Eric C. HOLLAND et al, "Modeling mutations in the G <sub>1</sub> arrest pathway in human gliomas: overexpression of CDK4 but not loss of INDAARF induces hyperploidy in cultured mouse astrocytes", Genes & Development, Vol. 12, 1998, pp. 3644-3649.	

Examiner Signature

*Karen A. Ganella*

Date Considered


2/6/02

\*EXAMINER: Initial ✓ reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Shee

of 2

**Complete if Known**

**Application Number**

**Filing Date**

**First Named Inventor**

Group Art Unit

Examiner Name \_\_\_\_\_

Attorney Docket Number 001107 00074

NOV 13 2001

— 1 —

~~TELEENTER 1600/2900~~

#### **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>KAZ</i>		Maria K. MATEYAK et al, c-Myc Regulates Cyclin D-Cdk4 and -Cdk6 Activity but Affects Cell Cycle Progression at Multiple Independent Points", Molecular and Cellular Biology, Vol. 19, No. 7, 1999, pp. 4672-4683.	
<i>KAZ</i>		Jaromir VLACH et al, "Growth arrest by the cyclin-dependent kinase inhibitor p27 KIP1 is abrogated by c-Myc", The EMBO Journal, Vol. 15, No. 23, 1996, pp. 6595-6604.	

Examiner Signature	Karen A. Canella	Date Considered	2/6/02
--------------------	------------------	-----------------	--------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.